DW-MRI for Sarcoma in Young Patients

ME
Overseen ByMary E. McCarville, MD
Age: Any Age
Sex: Any
Trial Phase: Academic
Sponsor: St. Jude Children's Research Hospital
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The trial aims to explore a new method for imaging tumors in children with bone or soft tissue sarcomas, using Diffusion Weighted Magnetic Resonance Imaging (DW-MRI). Unlike other imaging techniques that use radiation, DW-MRI avoids exposing children to harmful radiation, potentially making it safer. Researchers aim to determine if this method is as effective at assessing tumor response to treatment as current methods. Suitable candidates for this trial include children with a newly diagnosed bone or soft-tissue sarcoma who have not yet started therapy or can undergo research imaging shortly after beginning treatment. As an unphased trial, this study provides a unique opportunity for patients to contribute to safer imaging techniques for future pediatric cancer care.

Will I have to stop taking my current medications?

The trial protocol does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.

What prior data suggests that this imaging technique is safe for children?

Research has shown that Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) is safe because it doesn't use harmful radiation. This is particularly important for children, whose bodies are more sensitive to radiation. Studies in adults have demonstrated that DW-MRI can effectively track tumor response to treatment. Although its use in children is still under investigation, early results suggest it could serve as a reliable alternative to other imaging methods that involve radiation. Overall, DW-MRI appears well-tolerated, with no major safety concerns reported.12345

Why are researchers excited about this trial?

Researchers are excited about using diffusion-weighted magnetic resonance imaging (DW-MRI) for sarcoma in young patients because it offers a non-invasive way to assess the tumor's characteristics and response to treatment. Unlike standard imaging techniques, DW-MRI provides detailed information about the movement of water molecules in tissues, helping to distinguish between different types of tissue and detect changes in the tumor early on. This method has the potential to improve treatment planning and monitoring without the need for repeated biopsies or exposure to radiation.

What evidence suggests that DW-MRI is effective for assessing sarcoma in young patients?

Research has shown that a type of MRI scan called diffusion weighted MRI (DW-MRI) might be useful for tracking how tumors in children respond to treatment. Studies in adults have found that DW-MRI effectively monitors cancer treatment by revealing changes in tumor tissues. It distinguishes between types of sarcoma tumors, such as non-cancerous (benign) and cancerous (malignant) ones, as well as between more aggressive (high-grade) and less aggressive (low-grade) tumors. Although this technology is still new for children, early results suggest it could lower radiation exposure compared to traditional scans like CT or PET-CT. Reducing radiation is crucial for children, who are more sensitive to its harmful effects. Participants in this trial will undergo DW-MRI at several time points to evaluate its effectiveness in young patients with sarcoma.678910

Who Is on the Research Team?

ME

Mary E. McCarville, MD

Principal Investigator

St. Jude Children's Research Hospital

Are You a Good Fit for This Trial?

This trial is for young patients at St. Jude with newly diagnosed bone or soft tissue sarcomas who haven't started treatment yet. They must have had or be scheduled for a PET-CT/bone scan and can undergo MRI within 2-5 days of starting therapy. It's not for those needing immediate tumor resection, ICU patients, those unable to meet MRI safety requirements, or if sedation is risky due to certain health conditions.

Inclusion Criteria

I have had or will have a PET-CT or bone scan within 2 weeks of my MRI.
My age or gender does not affect my eligibility.
Informed consent or assent signed by study subject or parent/guardian according to institutional guidelines
See 2 more

Exclusion Criteria

Subject does not meet institutional MRI safety screening requirements
I do not have any current heart or lung conditions that would prevent me from safely receiving sedation for an MRI.
My tumor is scheduled for surgical removal soon.
See 4 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Imaging

Whole body and primary tumor diffusion weighted imaging (DWI) performed at baseline

1 week
1 visit (in-person)

Treatment Imaging

Additional DW-MRIs performed up to 3 times during treatment at the same time as routine MRI examinations

18 weeks
Up to 3 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment until completion of local control

Up to 5 years

What Are the Treatments Tested in This Trial?

Interventions

  • Diffusion Weighted Magnetic Resonance Imaging
Trial Overview The study tests whether whole body diffusion weighted magnetic resonance imaging (DW-MRI), which doesn't use harmful radiation, can effectively measure tumor response in pediatric sarcoma patients compared to current methods that do use radiation.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: ParticipantsExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

St. Jude Children's Research Hospital

Lead Sponsor

Trials
451
Recruited
5,326,000+

Citations

Role of diffusion-weighted MR imaging in the initial ...The DWI sequence may be useful for differentiating between benign and malignant lesions and between high- and low-grade sarcoma tumors, increasing the ...
Radiomics of diffusion-weighted MRI compared to ...Several previous studies demonstrated increased diagnostic accuracy of malignant soft tissue sarcoma by obtaining additional DWI with standard ...
Quantitative diffusion-weighted MRI response assessment ...To investigate the feasibility of diffusion-weighted magnetic resonance imaging (DW-MRI) as a predictive imaging marker after neoadjuvant chemotherapy in ...
Diffusion-weighted MR imaging diagnostic merits in the ...... Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J ...
Prediction of soft tissue sarcoma response to radiotherapy ...Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J ...
Diffusion Weighted Magnetic Resonance in Imaging ...Diffusion weighted magnetic resonance imaging (DWI MRI) is a method that does not involve radiation and can be used to assess the primary tumor as well as to ...
Staging Pediatric Bone and Soft-Tissue Sarcomas - PMCWhole-body diffusion-weighted MRI demonstrated agreement with conventional imaging and higher lesion sensitivity but lower specificity than PET/ ...
DW-MRI for Sarcoma in Young Patients · Info for ParticipantsResearch shows that Diffusion Weighted Imaging (DWI) can help assess how well a tumor is responding to cancer treatment and improve the evaluation of tumor ...
Diffusion Weighted Magnetic Resonance in Imaging ...This clinical trial studies diffusion weighted magnetic resonance imaging (DW-MRI) in imaging younger patients with newly diagnosed bone or soft tissue sarcomas ...
Diffusion Weighted Magnetic Resonance in Imaging ...To compare the ability of WB MRI, PET-CT and PET-CT + bone scan to detect all sites of metastases in pediatric sarcoma patients using biopsy and ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security